好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Can Clinical Scores Predict the Presence of Hypoxic Ischemic Brain Injury on Early Head Computed Tomography After Cardiac Arrest?
Neuro Trauma and Critical Care
P6 - Poster Session 6 (8:00 AM-9:00 AM)
2-001

Evaluate the Full Outline of Unresponsiveness (FOUR) and revised post-Cardiac Arrest Syndrome for Therapeutic hypothermia (rCAST) scores for predicting hypoxic ischemic brain injury (HIBI) on early head computed tomography (CT) following cardiac arrest (CA).

HIBI on early head CT is associated with poor neurologic outcome and brain death.

In this single-center, retrospective study of CA patients admitted between 2014-2022, early head CT was defined as within 6 hours of CA and HIBI was scored if early head CT radiology report documented 1) loss of gray-white matter differentiation, 2) sulcal effacement, 3) cerebral edema. Area under the receiver operating curve (AUC) was computed to assess rCAST and FOUR scores’ accuracy for predicting HIBI on early head CT.

Early head CT was performed in 55.5% (420/757) of patients; 108 (25.7%) had HIBI. Patients with HIBI were younger (mean (standard deviation) 50.7 (15.8) vs. 62.0 (16.7) years, p<0.001), healthier (median [interquartile range] Charlson Comorbidity Index 2 [0;4] vs. 4 [1;6], p <0.001), and presented with more severe post-CA syndrome (initial lactate 12.2 (4.6) vs. 8.5 (4.2), p<0.001; initial pH 7.23 (0.2) vs. 7.28 (0.2), p=0.011; rCAST 11.5 (3.7) vs. 8.3 (3.9), p<0.001; FOUR score 0.9 (1.5) vs. 3.6 (3.4), p <0.001). HIBI was associated with lower hospital survival (1.9% vs. 29.5%, p <0.001). The AUC of the rCAST and FOUR score for predicting HIBI were 0.735 [0.659; 0.811] and 0.762 [0.702; 0.826], respectively.

Just over half of our CA cohort underwent early head CT and one in four had HIBI, which was associated with high mortality. Available, valid scores (FOUR and rCAST) associated with CA outcome may be helpful in early head CT patient selection. These findings warrant validation in a larger prospective cohort not limited by early withdrawal of life-sustaining therapy.

Authors/Disclosures
Christine Nguyen
PRESENTER
Miss Nguyen has nothing to disclose.
Brandon Molligoda (Brandon Molligoda) Mr. Molligoda has nothing to disclose.
Noah Kim No disclosure on file
Eva Kitlen No disclosure on file
Charles Wira Charles Wira has nothing to disclose.
Sarah Perman No disclosure on file
Akhil Khosla Akhil Khosla has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Inari.
P Elliott Miller P Elliott Miller has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JCF-I.
David M. Greer, MD, FAAN (Boston University School of Medicine) Dr. Greer has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Thieme, Inc. Dr. Greer has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for multiple. Dr. Greer has received publishing royalties from a publication relating to health care. Dr. Greer has received publishing royalties from a publication relating to health care. Dr. Greer has received publishing royalties from a publication relating to health care. Dr. Greer has a non-compensated relationship as a Treasurer-Elect with American Neurological Association that is relevant to AAN interests or activities. Dr. Greer has a non-compensated relationship as a President with Neurocritical Care Society that is relevant to AAN interests or activities.
Emily J. Gilmore, MD (Yale University School of Medicine) Dr. Gilmore has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for carpl.ai. Dr. Gilmore has received personal compensation in the range of $0-$499 for serving as a Consultant for AAN. Dr. Gilmore has received research support from NIH.
Rachel Beekman, MD (Yale New Haven Medical Center) Dr. Beekman has nothing to disclose.